RCUS Quick Ratio | Arcus Biosciences, Inc.

Arcus Biosciences, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Arcus Biosciences, Inc. quick ratio for the quarter ending 2026-06-30 was 0.76, a 35.85% decline year-over-year.
Arcus Biosciences, Inc. quick ratio for the quarter ending 2026-03-31 was 0.96, a 3.83% decline year-over-year.
Arcus Biosciences, Inc. quick ratio for the quarter ending 2025-12-31 was 0.96, a 44.80% increase year-over-year.
Arcus Biosciences, Inc. quick ratio for the quarter ending 2025-09-30 was 1.01, a 8.33% increase year-over-year.
Arcus Biosciences, Inc. quick ratio for fiscal 2025 was 0.96, a 44.80% increase from fiscal 2024.
Arcus Biosciences, Inc. quick ratio for fiscal 2024 was 0.66, a 3.84% decline from fiscal 2023.
Arcus Biosciences, Inc. quick ratio for fiscal 2023 was 0.69, a 35.33% decline from fiscal 2022.
Arcus Biosciences, Inc. quick ratio for fiscal 2022 was 1.07, a 19.72% increase from fiscal 2021.

Available history: 2017-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	0.76	$150M	$198M
2026-03-31	0.96	$201M	$209M
2025-12-31	0.96	$222M	$231M
2025-09-30	1.01	$238M	$235M
2025-06-30	1.18	$248M	$210M
2025-03-31	1	$192M	$192M
2024-12-31	0.66	$150M	$226M
2024-09-30	0.93	$201M	$215M
2024-06-30	0.78	$156M	$199M
2024-03-31	0.91	$185M	$204M
2023-12-31	0.69	$127M	$184M
2023-09-30	0.92	$184M	$200M
2023-06-30	1.28	$230M	$180M
2023-03-31	1.33	$238M	$179M
2022-12-31	1.07	$206M	$193M
2022-09-30	1.23	$218M	$177.18M
2022-06-30	1.66	$273M	$164.02M
2022-03-31	3.4	$549M	$161.25M
2021-12-31	0.89	$148M	$166M
2021-09-30	1.26	$179.43M	$142.87M
2021-06-30	2.46	$320.48M	$130.37M
2021-03-31	2.96	$390.26M	$132.06M
2020-12-31	1.43	$173.42M	$121.67M
2020-09-30	1.36	$221.85M	$162.87M
2020-06-30	7.13	$285.19M	$40.03M
2020-03-31	3.21	$67.33M	$21M
2019-12-31	2.55	$57.94M	$22.71M
2019-09-30	3.75	$78.99M	$21.06M
2019-06-30	2.87	$76.07M	$26.51M
2019-03-31	3.6	$68.5M	$19M
2018-12-31	4.2	$71.06M	$16.94M
2018-09-30	4.51	$74.89M	$16.61M
2018-06-30	10.38	$170M	$16.38M
2018-03-31	13.89	$198.12M	$14.26M
2017-12-31	7.73	$98.43M	$12.73M

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	0.96	$222M	$231M
2024-12-31	0.66	$150M	$226M
2023-12-31	0.69	$127M	$184M
2022-12-31	1.07	$206M	$193M
2021-12-31	0.89	$148M	$166M
2020-12-31	1.43	$173.42M	$121.67M
2019-12-31	2.55	$57.94M	$22.71M
2018-12-31	4.2	$71.06M	$16.94M
2017-12-31	7.73	$98.43M	$12.73M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Organon & Co. (OGN)	United States	$3.603B	17.03
PRECIGEN, INC. (PGEN)	United States	$2.757B	-12.94
NewAmsterdam Pharma Co N.V. (NAMS)		$2.719B	-15.37
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
MBX Biosciences, Inc. (MBX)	United States	$2.664B	-25.36